Red Flags Detected

• ⚠ Material Weakness (new) — The company discloses it may identify material weaknesses in internal controls, which could lead to financial misstatements.
• ⚠ Chinese Company (new) — A Chinese company holds a significant equity stake, exposing the company to geopolitical and regulatory risks.
• ⚠ Single Product Candidate (new) — The company is substantially dependent on the success of its only product candidate, BHB-1893.
• ⚠ Reliance On Hengrui Clinical Data (new) — The company relies on clinical data generated by Hengrui from trials not designed or conducted by Braveheart, which may not be adequate for regulatory submissions.
• ⚠ Dilution (new) — New investors face immediate dilution of $11.41 per share, with existing holders having paid an average of $2.41 per share.